Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Tianyin Pharmaceutical Co., Inc.
CHENGDU, China, Feb. 9, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the second quarter of fiscal year 2014 ended December 31, 2013 to be held at 9:00 a.m. ET on Friday, February 14th, 2014.
Interested parties may access the call by dialing:
Conference ID: 4667572
It is advisable to dial in approximately 5 minutes prior to the start of the call.
Replay Dial-In Numbers:
From: 02/14/14 @ 12:00 pm Eastern Time
To: 02/28/14 @ 11:59 pm Eastern Time
Replay Pin Number: 4667572
This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=107804
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list (EDL) of China. For more information about TPI, please visit: http://www.tianyinpharma.com
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
Tel: +86-28-8551-6696 (Chengdu, China)
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
©2012 PR Newswire. All Rights Reserved.